舌下减敏临床治疗花粉过敏成效高

纽约（华盛顿邮报卫生专栏）12月21日电—据《变态反应，哮喘及免疫学年鉴》杂志11周刊一篇华盛顿邮报，舌下减敏临床（SLIT）外科手术花粉抑止的呼吸道过敏成效高。“来进行SLIT减少咳嗽的并发症及本品消费，减轻社会贫困，”那不勒斯Genoa大学Giovanni Passalacqua芝加哥大学真是。“先前已经有大幅提高注射临床减轻社会负担，但这是首次对简单临床（SLIT）进行严格评量的结果。”Passalacqua芝加哥大学及其同事们对花粉抑止的过敏性咳嗽和哮喘治果进行研究工作，评量来进行SLIT结合标准外科手术及基本上来进行标准外科手术的费用及。研究工作职员华盛顿邮报，SLIT使63.1%的患儿症状改善，并预防51.8%的患儿显现哮喘，而基本上运用标准临床仅仅使23.2%的患儿症状改善，预防28.9%的患儿显现哮喘。而且同标准外科手术相比，SLIT的直接及间接要花费均增高：SLIT患儿外科手术的总体要花费大于国家所卫生保健子系统预测的4年内基本上本品外科手术要花费，并且大于社会大众预测的2年内基本上本品外科手术要花费。“SLIT并很难称得上大幅提高注射临床的即使如此，” Passalacqua芝加哥大学解释真是，“而是将其作为外科手术方法的另一选取。它最大的优点在于其最优的安全性和患儿的易接受性。”“SLIT在宾夕法尼亚州并未月运用，尽管一些变态反应专家运用它（并且获取了满意的结果），” Passalacqua芝加哥大学真是。“欧洲情况完全不同，SLIT在很多国家所之中广泛运用（如那不勒斯，德国，法国，巴伦西亚，智利，希腊及保加利亚）。”这两项的问题是SLIT并未得不到FDA的首肯，“Passalacqua芝加哥大学多余道。“受到FDA支持的临床研究工作正在进行之中，并有望得不到首肯。” Sublingual Immunotherapy Cost-Effective for Pollen-Induced AllergyBy Will Boggs, MDNEW YORK (Reuters Health) Dec 21 - Sublingual immunotherapy (SLIT) is cost-effective for treating s with pollen-induced respiratory allergy, according to a report in the November Annals of Allergy, Asthma Wild Immunology."The use of SLIT leads to a socio-economic sings by reducing the comorbidities of rhinitis and drug consumption," Dr. Giovanni Passalacqua from University of Genoa, Italy told Reuters Health. "This fact has been previously envisaged also for injection IT, but this is the first rigorous assessment made by means of a validated economic model."Dr. Passalacqua and colleagues' study was designed to evaluate the costs and consequences of using SLIT in association with standard treatment compared with standard treatment alone in young s with pollen-induced allergic rhinitis and asthma.SLIT improved symptoms of 63.1% of patients and prevented asthma in 51.8% of patients, the authors report, compared with 23.2% and 28.9%, respectively, of patients receiving standard treatment.Compared with standard treatment, SLIT resulted in lower direct and indirect expenses, the researchers note.According to the results, the overall cost of treatment for SLIT patients drops below that for patients receiving only drugs at year 4 from the National Healthcare System perspective and at year 2 from the societal perspective."SLIT is not to be intended as an antagonist of injection IT," Dr. Passalacqua explained, "rather as an additional therapeutic option. Its best advantage is the optimal safety profile and the good acceptance by the patients.""SLIT is not officially in use in the USA, although some allergists utilize it (with satisfactory results)," Dr. Passalacqua said. "In Europe the situation is completely different, and SLIT is widely used in many countries (e.g., Italy, Germany, France, Spain, Portugal, Greece, and Hungary).""The problem is formal, due to the fact that SLIT has not the approval of the FDA," Dr. Passalacqua added. "Clinical studies endorsed by the FDA are currently ongoing to get the approval."Ann Allergy Asthma Immunol 2006;97:615-621.

校对：蓝色幻想